🚦 Green light for launch? Not so fast—your FTO analysis can make or break the first day of revenue.
In pharma, the moment you announce a “launch-ready” product, the clock starts ticking—not just on manufacturing timelines, but on patent risk. A sing…

Biotech investors don’t lose money because they can’t read a press release.
They lose money because they read the wrong numbers.
In a sector where one trial update can swing a stock 30% in a day, “headline metrics” are often just noise—useful for story…

Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System (Explained)
In pharma, “protection” isn’t one thing—it’s two.
And if you’re an investor, operator, or policy watcher, understanding the difference between patent exclusi…

First-to-File, First-to-Profit: The Hidden Math Behind Paragraph IV and 180-Day Exclusivity
If you’ve ever wondered why some generic launches feel like they happen “overnight” while others drag on for years, the answer is often sitting in a single phra…

Generic and biosimilar launches don’t fail because the science is wrong—they fail because the timing is.
In managed care, pharmacy teams live in the uncomfortable gap between regulatory reality and contractual execution. A product loses exclusivity, …

Most pharma teams don’t lose because they’re out of talent. They lose because they’re out of time.
By the time a competitor’s “official” pipeline hits the public domain—conference slides, press releases, even the first whispers in a journal—your window…

20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
Most people think drug patent life is a simple countdown: file today, expire in 20 years. In practice, the clock is messier—and the difference between “theoretical” and “act…

Research suggests that selenium deficiency can have a negative impact on hair and nail health 1. This essential mineral plays… https://www.Drugchatter.com/chat/53847/can-selenium-affect-hair-and-nail-health/

Pick the Right Patent—or Leave Billions on the Table: The “One Patent Per Product” Rule and the PTE Playbook
In pharma, the difference between a breakthrough and a blockbuster can come down to a single decision made years earlier—often before the marke…

South America is often treated as one market—one story, one risk profile, one regulatory rhythm. But in drug development and IP strategy, that shortcut is expensive.
A new country-by-country breakdown from DrugPatentWatch makes the case clearly: South …